Is there a role for vitamin D in supporting cognitive function as we age?

Niamh Aspell¹*, Brian Lawlor² and Maria O'Sullivan¹

¹Department of Clinical Medicine, School of Medicine, Trinity Centre for Health Sciences, St. James's Hospital Campus, Dublin, Ireland
²Department of Psychiatry, Mercer's Institute for Successful Ageing, St. James's Hospital, Dublin, Ireland

Globally, an estimated 46 million people are currently living with dementia and this figure is projected to increase 3-fold by 2050, highlighting this major public health concern and its substantial associated healthcare costs. With pharmacological treatment yet to reach fruition, the emphasis on evidence-based preventative lifestyle strategies is becoming increasingly important and several modifiable lifestyle factors have been identified that may preserve cognitive health. These include good cardiovascular health, physical activity, low alcohol intake, smoking and a healthy diet, with growing interest in vitamin D. The aim of the present paper is to review the evidence supporting the potential roles of vitamin D in ageing and cognitive health in community-dwelling older adults. Furthermore, to describe the utility and challenges of cognitive assessments and outcomes when investigating vitamin D in this context. Evidence indicates that serum 25-hydroxyvitamin D (25(OH)D) may impact brain health. There is a biological plausibility from animal models that vitamin D may influence neurodegenerative disorders, through several mechanisms. Epidemiological evidence supports associations between low serum 25(OH)D concentrations and poorer cognitive performance in community-dwelling older populations, although an optimal 25(OH)D level for cognitive health could not be determined. The effect of raising 25(OH)D concentrations on cognitive function remains unclear, as there is a paucity of interventional evidence. At a minimum, it seems prudent to aim to prevent vitamin D deficiency in older adults, with other known common protective lifestyle factors, as a viable component of brain health strategies.

Alzheimer’s disease: Cognition: Vitamin D deficiency: 25-hydroxyvitamin D: Successful ageing

As we experience population ageing more of us can expect to reach and enjoy our old age. This demographic shift should be seen as a time of opportunity; however, as a result, we are also experiencing an increase in age-related diseases. The global incidence of dementia is increasing at a rate of one new case every 3 s, with associated medical, social and healthcare costs far exceeding the capacity of most countries. Dementia is a syndrome, usually progressive and chronic in nature, in which there is deterioration in cognitive function beyond what might be expected from normal ageing. Due to the degenerative nature of the disease, sufferers lose their ability to perform routine tasks, experience poor quality of life and a loss of autonomy. In 2017, Public Health England reported dementia to be the leading cause of death in older adults in England, overtaking CVD, stroke and lung cancer for the first time. Similar trends have been expressed globally, which are largely driven by our increasing older adult population, longer life expectancies and improved diagnostic procedures.

In the absence of curative treatments, the focus on maintaining cognitive health, reducing the risk of developing dementia and delaying the onset is now a key priority for public health authorities and governments.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; AD, Alzheimer’s disease; UV-B, ultraviolet B; VDR, vitamin D receptor.

*Corresponding author: N. Aspell, email niamha@tcd.ie
Dementia risk increases with advancing age, family history and genetic factors, for example, carriers of ApoE ε4 genotype. Dementia is of course, not an inevitable consequence of older age. Several modifiable lifestyle factors have been identified including CVD, diabetes, smoking and obesity. Indeed modifiable factors may promote resilience in ApoE ε4 gene carriers. A role for vitamin D in the aetiology of cognitive impairment and dementia is plausible, supported by substantial mechanistic and epidemiological data, although intervention studies remain sparse. Vitamin D is a steroid hormone, which directly or indirectly regulates thousands of genes acting mainly via the vitamin D receptor (VDR). The VDR is expressed on multiple tissue sites, including the brain, cardiovascular and musculoskeletal systems where it acts on the expression of several gene target products as well as a range of non-genomic effects. An estimated one billion people globally are vitamin D insufficient which provides an opportunity for intervention. The aim of the present review is to discuss vitamin D in ageing and examine the evidence for the potential role of vitamin D deficiency and brain health and possible levels likely to support cognitive performance in community-dwelling older adults. Furthermore, we aim to consider the complexities of investigating the effects of vitamin D on cognitive outcomes in ageing.

**Vitamin D physiology: a focus on ageing**

**Vitamin D metabolism**

Vitamin D is a precursor of the active form 1,25-dihydroxyvitamin D (calcitriol) and is present in two forms; vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). The main source in human subjects is via action of solar ultraviolet-B (UV-B) radiation (270–300 nm) on skin, converting 7-dehydrocholesterol (provitamin D3) into previtamin D3, which is then rapidly converted to vitamin D3. Vitamin D3 is produced via UV-B radiation on plant sources such as mushrooms and yeast. Natural dietary sources of vitamin D2 are few and include fish liver oils, oily fish, egg yolks and some fortified foods (e.g. some dairy and breakfast cereals) and supplements. Irrespective of how it is acquired, vitamin D offers limited function until it has been activated, a process which requires two hydroxylation steps. Firstly in the liver by a number of enzymes but primarily vitamin D3-25-hydroxylase (CYP2RA), which converts it to the inactive precursor, 25-hydroxyvitamin D (25(OH)D), the prominent circulating form used to determine vitamin D status in human subjects. The second hydroxylation step occurs in the tubular cells of the kidney, by action of the enzyme 25vitamin D3-1α-hydroxylase (CYP27B1), to the biologically active metabolite, 1,25-dihydroxyvitamin D3. This active metabolite is an important modulator of calcium and phosphate homeostasis, importantly; however, both the activating enzyme CYP27B1 and the active form of vitamin D, 1,25-dihydroxyvitamin D3, are present in many non-renal tissues including the human brain, immune cells, cardiovascular systems and pancreatic islets. Due to the ability to be synthesised endogenously, vitamin D is widely accepted not as a classical vitamin but as a steroid hormone, furthermore, its synthesis in the human brain has led to it being commonly referred to as a neurosteroid.

**Factors influencing vitamin D status in ageing**

Several factors influence vitamin D status including skin pigmentation, use of sunscreen or concealing clothing, season, latitude, being older or institutionalised, obesity, malabsorption, renal and liver disease and medication use. In general, UV-B radiation on skin is the main source of vitamin D for human subjects. In countries north of the equator (40–60°N), vitamin D UV-B doses are inadequate for 6 months of the year (October–March). Many other environmental factors implicate vitamin D UV-B dose availability including the ozone layer, cloud cover, air pollution, surface reflection and altitude. With advancing age skin integrity decreases; skin thinness and a reduction in transdermal cholesterol reduce the efficiency of UV-B vitamin D production, as much as 50% in older adults compared with younger adults. Behavioural and social changes seen with advancing age further limit cutaneous vitamin D production. Less time spent outdoors due to ill health or limited mobility (institutionalised or homebound), medication use (loop diuretics, statins, glucocorticoids), changes in body composition (increase in fat and decrease in muscle), sun avoidance (melanoma risk), reduced skin exposure (clothing and colder temperatures) and sunscreen use are all significant barriers that contribute to inadequate UV-B vitamin D production in older adults. Evidence suggests vitamin D supplement uptake is typically low in the population, including older adults. For the most part, dietary sources are limited and not generally consumed in adequate amounts by older adults, with an exception for those residing in countries where vitamin D food fortification is in place (United States, Canada, Sweden and Finland). The effects of age on intestinal absorption and decreased renal function may hinder vitamin D metabolism and availability. It has been hypothesised that the metabolism of vitamin D may be reduced due to a decline of intestinal VDR distribution in older adults; however, few studies have been conducted in human subjects, with small samples and conflicting findings.

**Vitamin D deficiency and ageing**

Serum 25(OH)D is accepted as the most accurate measure of vitamin D status; however, there is less agreement on how to define deficiency in the general population or specifically to older adults. The Institute of Medicine advocate serum 25(OH)D concentrations ≥50 nmol/l (≥20 ng/ml) for bone health, and with levels <30 nmol/l (<12.5 ng/ml) considered to be deficient. The term
vitamin D insufficiency is used to describe serum levels of
≥30–50 nmol/l (≥12.5–20 ng/ml)\(^\text{(35)}\). In contrast, the endocrine society recommends serum 25(OH)D levels
>75 nmol/l to maximise an effect on bone and muscle metabolism. Suboptimal levels of vitamin D are much
more common than clinical toxicity which is rare\(^\text{(36)}\). Reported vitamin D deficiency rates in published studies vary widely, with considerable methodological differences
including the definition of serum 25(OH)D status, sample size, population, sex-specific cohorts, latitude, season and mode of vitamin D assay. Prevalence estimates for vitamin D deficiency in community-dwelling
older adults across the European Union and the UK are summarised in \(\text{(Table 1)}\), along with the specific
25(OH)D cut-off criteria applied to define deficiency. As illustrated in \(\text{(Table 1)}\), deficiency ranged from 0 to
100 %. Overall, however, it is apparent that suboptimal vitamin D status is widespread in older adults, irrespective
of the definition applied. For example, the Health Survey in England reported that 13 % of females and
8 % of males were vitamin D deficient, using the more conservative cut-off of <20 nmol/l\(^\text{(37)}\), at 5 years
follow-up deficiency rates increased to 15 and 9-6 %, respectively\(^\text{(38)}\). When defining criteria is set at <50
nmol/l, 62.5 % of females and 50 % of males were classed as vitamin D deficient in this community-dwelling
cohort. However, deficiency rates were almost double in cohorts defined as cognitively impaired\(^\text{(39)}\). In a recent
study of Irish adults, a 10 % higher prevalence of vitamin D deficiency was reported in adults aged 65 years and
older compared to middle-aged adults, 35·7 and 44·0 %, respectively\(^\text{(28)}\).

\textbf{Vitamin D and cognitive function in ageing: considerations for assessment and outcome measures}

The concept that cognitive function can be influenced by
diet or specific nutrients has garnered interest in recent
years. One of the most formidable methodological bar-
riers evident across nutrition and cognition studies is
the heterogeneity in cognitive assessments used, which
will ultimately influence the outcome and the interpre-
tation of the findings.

The term cognitive function refers to a variety of brain
functions and processes which include receiving internal
information, processing this internally and responding
with a behaviour. It can be seen as a hierarchy, going
from overall (global) to domain-specific cognitive function.
The most commonly used cognitive outcome measure in
vitamin D studies are global tests, namely the
Mini-Mental State Examination, and consequently, most
associations were seen with a global measure\(^\text{(40–44)}\). Whilst this clinical screening test is widely used, it has limited use
in research for detecting subtle changes in cognitive function in
response to short-term interventions, such as vitamin D
supplementation trials\(^\text{(45)}\). Domain-specific functions
include memory, executive functioning, attention, percep-
tual functions, psychomotor abilities and language skills.
Domain-specific measures are useful but reliance on a
single domain assessment may lead to cognitive changes
going undetected due to intra-individual variability\(^\text{(46)}\).
Assessing cognitive function is complex and the import-
ance of utilising multiple domains and assessing further
sub-processes within each domain has been highlighted
in recent years\(^\text{(47)}\).

Inter-individual performance in different domains vary and each individual has a unique profile of strengths
and weaknesses in different domains\(^\text{(48)}\), so it is not expli-
cit to define people on global function or domain-specific
function alone. Performing well on one domain is often
dependent on traits of another cognitive process or
domains, for example, retaining new information in a
memory test is highly dependent on attention\(^\text{(49)}\).

Studies which report having assessed participants’ cogni-
tive function but use only a single domain outcome meas-
ure should be interpreted with caution unless the
hypothesis predicts a specific effect on memory; even
then including a mix of tests will better determine
whether the predicted memory-specific function was
indeed affected specifically.

\textbf{Other factors related to cognitive assessments}

Each domain is highly influenced by other mental fac-
tors, a psychological concept called central arousal which
describes internal states such as mental fatigue and
needs to be considered when assessing cognitive per-
formance\(^\text{(50)}\). Mood, sleep, anxiety and depression are
highly correlated with cognitive performance and can
significantly alter the outcome\(^\text{(51,52)}\).

The assessment of cognitive function is further compli-
cated in defining the cognitive status of study partici-
pants, a distinct difference must be acknowledged when
considering cognitive changes which are age-related
and those which are a result of disease. Furthermore,
inter-individual variability in the form and severity of
cognitive decline is largely influenced by education and
health-related factors. To accurately assess changes in
cognitive status, these factors must also be considered,
whilst acknowledging that older adults vary widely in
the extent to which they are affected by these changes\(^\text{(48)}\).

For example, to our knowledge, no studies of vitamin D
status and cognitive performance considered assessment
of pre-morbid IQ, which is highly correlated with most
cognitive tests, since decline is essentially relative to pre-
morbid ability\(^\text{(53)}\), a score within the ‘normal’ range can,
in fact, represent cognitive decline for an individual with
high levels of pre-morbid functioning.

\textbf{Types of outcome measures commonly used in vitamin D
and cognition research}

Neuropsychological performance tests are the methods
most commonly used in vitamin D and cognition studies.
Cognitive function can be assessed by a number of vali-
dated pen-and-paper or computer-based tests. Direct
measures of brain location and effectiveness of many
cognitive processes can be assessed using electroencepha-
lograms, or assessment of brain activation associated
with specific domains of cognitive function through
Table 1. Prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency in community-dwelling adults, aged over 50 years in Europe

<table>
<thead>
<tr>
<th>nmol/l</th>
<th>Lead author(s)</th>
<th>Year</th>
<th>Location</th>
<th>Cohort</th>
<th>N</th>
<th>% D-def</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10</td>
<td>Cooper et al. (124)</td>
<td>1989</td>
<td>UK</td>
<td>Hip fracture patients, females only</td>
<td>41</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Vir &amp; Love (125)</td>
<td>1978</td>
<td>UK</td>
<td>Outpatients</td>
<td>37</td>
<td>42</td>
</tr>
<tr>
<td>&lt;15</td>
<td>Solanki et al. (126)</td>
<td>1995</td>
<td>UK</td>
<td>Asian population (n 37), White population (n 19)</td>
<td>56</td>
<td>57/6</td>
</tr>
<tr>
<td>&lt;20</td>
<td>Mavroeidi et al. (127)</td>
<td>2010</td>
<td>UK</td>
<td>Females only, North UK (White), South UK (Asian)</td>
<td>374</td>
<td>25/58-1</td>
</tr>
<tr>
<td></td>
<td>Lips et al. (128)</td>
<td>2006</td>
<td>EU</td>
<td>Combined countries, females only</td>
<td>1020</td>
<td>0-3-1</td>
</tr>
<tr>
<td></td>
<td>Lips et al. (129)</td>
<td>1987</td>
<td>NL</td>
<td>Community-dwelling controls</td>
<td>74</td>
<td>16</td>
</tr>
<tr>
<td>&lt;25</td>
<td>McCarroll et al. (130)</td>
<td>2015</td>
<td>IRL</td>
<td>Disease defined cohorts; CVD, Osteo, MCI</td>
<td>4444</td>
<td>17.2, 8-6, 32-8</td>
</tr>
<tr>
<td></td>
<td>Hirani et al. (131)</td>
<td>2010</td>
<td>UK</td>
<td>Health Survey Study (2005)</td>
<td>2070</td>
<td>13 (f) 8 (m)</td>
</tr>
<tr>
<td></td>
<td>Forouhi et al. (132)</td>
<td>2008</td>
<td>UK</td>
<td>MRC Ely Study (1990–2000)</td>
<td>524</td>
<td>5-5</td>
</tr>
<tr>
<td></td>
<td>Hill et al. (133)</td>
<td>2006</td>
<td>IRL</td>
<td>Community-dwelling, females only, late winter</td>
<td>95</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Hill et al. (132)</td>
<td>2005</td>
<td>IRL</td>
<td>Community-dwelling, females only</td>
<td>59</td>
<td>S:4, W:17-36</td>
</tr>
<tr>
<td></td>
<td>Hirani &amp; Primatesta (137)</td>
<td>2005</td>
<td>UK</td>
<td>Health Survey England (2003)</td>
<td>1217</td>
<td>15 (f) 9-6 (m)</td>
</tr>
<tr>
<td></td>
<td>Elia &amp; Stratton (138)</td>
<td>2005</td>
<td>UK</td>
<td>National Diet and Nutrition Survey</td>
<td>1155</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andersen et al. (134)</td>
<td>2005</td>
<td>EU</td>
<td>OPTIFORD study, females only</td>
<td>221</td>
<td>10, 25</td>
</tr>
<tr>
<td></td>
<td>Wolfe et al. (135)</td>
<td>1998</td>
<td>DE</td>
<td>EVOS study, population sample</td>
<td>580</td>
<td>24</td>
</tr>
<tr>
<td>&lt;30</td>
<td>McCarroll et al. (136)</td>
<td>2015</td>
<td>IRL</td>
<td>Disease defined cohorts; CVD, Osteo, MCI</td>
<td>4444</td>
<td>27.3, 13-8, 43-6</td>
</tr>
<tr>
<td></td>
<td>Andersen (134)</td>
<td>2005</td>
<td>EU</td>
<td>OPTIFORD study, females only</td>
<td>221</td>
<td>55-92</td>
</tr>
<tr>
<td></td>
<td>Boonen et al. (137)</td>
<td>1997</td>
<td>BEL</td>
<td>Outpatients fracture clinic, males only</td>
<td>40</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>van der Wielen et al. (138)</td>
<td>1995</td>
<td>EU</td>
<td>SENECA study, wintertime blood samples</td>
<td>824</td>
<td>47 (f) 36 (m)</td>
</tr>
<tr>
<td></td>
<td>Chapuy et al. (139)</td>
<td>1997</td>
<td>FR</td>
<td>20 French cities (43°–51°N)</td>
<td>1569</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Chapuy et al. (138)</td>
<td>1996</td>
<td>FR</td>
<td>EPIDOS study, females only</td>
<td>440</td>
<td>39</td>
</tr>
<tr>
<td>&lt;40</td>
<td>Macdonald et al. (139)</td>
<td>2008</td>
<td>SCT</td>
<td>APOS study, females only</td>
<td>3113</td>
<td>T:31:0,S:24:8,W:34:1</td>
</tr>
<tr>
<td></td>
<td>McCarthy et al. (140)</td>
<td>2006</td>
<td>IRL</td>
<td>Community-dwelling, females only</td>
<td>43</td>
<td>S:20, W:37:2</td>
</tr>
<tr>
<td></td>
<td>Lips et al. (132)</td>
<td>2006</td>
<td>EU</td>
<td>Combined countries, females only</td>
<td>1020</td>
<td>3-8-26</td>
</tr>
<tr>
<td>&lt;50</td>
<td>Cashman et al. (131)</td>
<td>2012</td>
<td>IRL</td>
<td>NANS Age 51–64 (n 80), age 65–84 (n 63)</td>
<td>143</td>
<td>35-7-44-0</td>
</tr>
<tr>
<td></td>
<td>Brouwer-Brolsma et al. (141)</td>
<td>2016</td>
<td>DNK</td>
<td>B-PROOF study</td>
<td>2544</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>McCarroll et al. (139)</td>
<td>2015</td>
<td>IRL</td>
<td>Disease defined cohorts; CVD, Osteo, MCI</td>
<td>4444</td>
<td>66-0, 43-4, 75-0</td>
</tr>
<tr>
<td></td>
<td>Forouhi et al. (132)</td>
<td>2008</td>
<td>UK</td>
<td>MRC Ely study</td>
<td>524</td>
<td>34-4</td>
</tr>
<tr>
<td></td>
<td>Lips et al. (132)</td>
<td>2006</td>
<td>EU</td>
<td>Combined countries, females only</td>
<td>1020</td>
<td>12-7-40-8</td>
</tr>
<tr>
<td></td>
<td>Hirani &amp; Primatesta (137)</td>
<td>2005</td>
<td>UK</td>
<td>Health Survey England (2000)</td>
<td>1217</td>
<td>62(2) 50 (m)</td>
</tr>
<tr>
<td></td>
<td>Hill et al. (132)</td>
<td>2005</td>
<td>IRL</td>
<td>Community-dwelling, females only</td>
<td>59</td>
<td>S:17, W:53</td>
</tr>
<tr>
<td>&lt;75</td>
<td>Macdonald et al. (139)</td>
<td>2008</td>
<td>SCT</td>
<td>APOS study, females only</td>
<td>3113</td>
<td>T:77:0,S:75:4,W:75:4</td>
</tr>
<tr>
<td></td>
<td>Forouhi et al. (130)</td>
<td>2008</td>
<td>UK</td>
<td>MRC Ely study</td>
<td>524</td>
<td>76-9</td>
</tr>
<tr>
<td></td>
<td>Lips et al. (132)</td>
<td>2006</td>
<td>EU</td>
<td>Combined countries, females only</td>
<td>1020</td>
<td>37-7-45</td>
</tr>
<tr>
<td></td>
<td>Hirani &amp; Primatesta (137)</td>
<td>2005</td>
<td>UK</td>
<td>Health Survey England (2000)</td>
<td>1217</td>
<td>86 (f) 79-5 (m)</td>
</tr>
<tr>
<td>&lt;80</td>
<td>Hill et al. (132)</td>
<td>2005</td>
<td>IRL</td>
<td>Community-dwelling, females only</td>
<td>59</td>
<td>S:63, W:85</td>
</tr>
<tr>
<td></td>
<td>Mavroeidi et al. (127)</td>
<td>2010</td>
<td>UK</td>
<td>Female, North UK (White) South UK (Asian)</td>
<td>374</td>
<td>80-7-100</td>
</tr>
</tbody>
</table>

D-def, serum 25(OH)D deficient; T, total; S, summer; W, winter; m, male; f, female.
* Deficiency defined <22.5 nmol/l
† Deficiency defined <37 nmol/l.

Vitamin D, ageing and cognitive function

Functional MRI, often considered the gold standard, however, like all tests is subject to limitations. The relationship between neuronal activity and functional ability is not fully understood and their use in measuring nutritional effects should be interpreted carefully. Emerging mobile technologies which obtain real-time information regarding abilities to perform activities of daily living, which are highly correlated with neuro-psychological tests, may change the way cognitive research is conducted, in way of preventative strategies for dementia.

As the evidence for an underlying link between vitamin D and cognitive performance remains inconclusive, the best approach is to include a battery of cognitive tests that cover a variety of domains; this may help identify the specific cognitive processes involved. Several large-scale ageing studies incorporate a comprehensive battery of validated cognitive tests; their use in cognitive studies on vitamin D may be helpful. However, the logistics, time and practicalities of applying comprehensive cognitive batteries in vitamin D studies may be a barrier. Recently we reported preliminary findings that this was feasible and acceptable in adults aged 60 years and older, at three time points over a 6-month period.

Epidemiological evidence; low vitamin D status and cognitive performance in healthy older adults

In the decade succeeding the discovery of the VDR and 1α-hydroxylase in the human brain, a plethora of evidence for a relationship between serum 25(OH)D and cognitive function has been presented. Data from healthy older adults without known cognitive impairment provides comparable evidence in terms of evaluating the contribution of vitamin D and successful ageing; however, this information is less plentiful. To date, the majority of cross-sectional studies support an association between hypovitaminosis D and poorer cognitive performance in healthy older adults.
performance. Yet many use only brief measures of cognitive function or adjust for few or limiting confounding factors. A recent cross-sectional study demonstrated that older adults with low 25(OH)D status (<30 nmol/l) performed significantly worse than those with levels >75 nmol/l, including greater processing speed and mental flexibility. This evidence was drawn from a well-designed large national study of ageing conducted in Amsterdam, which employed an in-depth cognitive assessment and gathered detailed demographic and lifestyle information. In contrast, the largest cross-sectional study conducted to date found no association between 25(OH)D status and cognitive function, comprising 4831 participants of the National Health and Nutrition Examination Survey. The result may be attributed to the single memory outcome measure used to assess cognitive function. Three large population cohorts have since demonstrated a significant relationship between low 25(OH)D status (typically <30 nmol/l) and poorer cognitive performance, using comprehensive global and domain-specific outcomes, compared with adequate 25(OH)D levels (typically >75 nmol/l). Other studies have demonstrated a relationship also, however, methodological issues were noted, with small sample sizes, limited analysis of confounding factors and single measures of cognitive performance. Cross-sectional studies are considered to provide weak evidence, due to the known issue of reverse causality, in that poorer cognitive performance or the onset of dementia may influence vitamin D concentrations through behavioural and dietary changes.

Longitudinal studies suggest that vitamin D deficiency is associated with an increased risk of cognitive impairment and incidence of dementia and Alzheimer’s disease (AD). One such study conducted with 10,186 older adults followed up after 30 years, revealed that those with 25(OH)D levels <25 nmol/l had a greater combined risk of developing AD than those with levels >50 nmol/l. Another prospective study revealed that those with 25(OH)D concentrations at baseline, and at 3- and 6-year follow-up performed worse in global function and executive functioning but not in tasks of attention. Whilst most studies demonstrate a link between serum 25(OH)D deficiency and poorer cognitive performance or incidence of dementia using a measure of global or domain-specific cognitive function, it is not clear if vitamin D deficiency is a risk factor for cognitive impairments or a result of poorer overall status and ill health.

**Intervention evidence; the effects of vitamin D supplementation on cognitive performance**

There are limited data from intervention studies. To date, three studies have been published investigating the effect of vitamin D supplementation on cognitive performance in healthy older adults. Overall one of three reported a significant positive effect on cognitive measures (Table 2). Recently, the first prospective intervention, using 50 μg/d (2000 IU) vitamin D₃ reported

---

**Table 2. Intervention studies; effect of vitamin D supplementation and cognitive performance outcomes in healthy older adults**

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Intervention</th>
<th>Cohort</th>
<th>Cognitive outcome</th>
<th>Results (adjusted)</th>
<th>Sign.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patterson et al. (60)</td>
<td>Randomised, double-blind, low dose placebo-controlled trial</td>
<td>T: 100 µg/d D₃ PL: 10 µg/d D₃</td>
<td>Healthy adults aged 20 years + n</td>
<td>No signif difference between groups</td>
<td>P = 0.11 (d = 0.4)</td>
<td>No</td>
</tr>
<tr>
<td>Amnueler et al. (61)</td>
<td>Pre-post, 12 months</td>
<td>T: 30 µg/d or 50 µg/d PL: 15 µg/d or 25 µg/d</td>
<td>Memory clinic n = 82</td>
<td>T: 75.0, PL: 75.0</td>
<td>T: 0.2, PL: 0.035</td>
<td>Yes</td>
</tr>
<tr>
<td>Rossom et al. (71)</td>
<td>Pre-post, 12 months</td>
<td>T: 50 µg/d or 250 µg/d PL: 10 µg/d or 50 µg/d</td>
<td>Healthy females aged 80-89</td>
<td>No signif difference between groups</td>
<td>P = 0.04 (d = 0.46)</td>
<td>No</td>
</tr>
<tr>
<td>-</td>
<td>Post-hoc analyses RT</td>
<td>T: 10 µg/d D₃ + Ca 1 g/month PL: 10 µg/d</td>
<td>Healthy females aged ≥65 years</td>
<td>No signif difference between groups</td>
<td>P = 0.009 (d = 0.22)</td>
<td>No</td>
</tr>
<tr>
<td>-</td>
<td>Post-hoc analyses RT</td>
<td>T: 1000 mg Ca, 25 µg/d vitamin D₃ + Ca 1 g/month PL: 10 µg/d</td>
<td>Healthy females aged ≥65 years</td>
<td>No signif difference between groups</td>
<td>P = 0.009 (d = 0.22)</td>
<td>No</td>
</tr>
<tr>
<td>-</td>
<td>Post-hoc analyses RT</td>
<td>T: 1000 mg Ca, 25 µg/d vitamin D₃ + Ca 1 g/month PL: 10 µg/d</td>
<td>Healthy females aged ≥65 years</td>
<td>No signif difference between groups</td>
<td>P = 0.009 (d = 0.22)</td>
<td>No</td>
</tr>
</tbody>
</table>

---

B. Hollander, PL. intervention: PL. phosphorus, DMSF, memory digit span test; DS-F, digit span forward; DS-B, digit span backward; CANTAB, Cambridge neuropsychological test automated battery; 25(OH)D, 25-hydroxyvitamin D; PRM, pattern recognition memory; PAL, paired associates learning; MMSE, mini-mental state examination; CAB, cognitive assessment battery; WHISCA, women’s health initiative study of cognitive aging; DSM-IV, diagnostic and statistical manual of mental disorders; MCI, mild cognitive impairment; Sig., significant.
no significant improvement in tasks of visual memory among eighty-two community-dwelling adults\(^{(69)}\). Of note, was the heterogeneity between participants, as only 30% of this small sample were aged over 60 years.

Annweiler et al.\(^{(70)}\), however, reported a positive finding in a small retrospective study (\(n\) 44), cognition was measured using a global measure and a behavioural assessment among patients attending an outpatient clinic, without cognitive impairment at baseline\(^{(70)}\). Incomplete 25(OH)D data were available for all participants, so determining optimal levels for cognitive performance are unobtainable from this investigation.

In the largest intervention study conducted to date, in community-dwelling females across the USA, no effect for vitamin D supplementation and incidence of dementia or cognitive performance was seen at follow-up (7-8 years)\(^{(71)}\). Whilst an in-depth cognitive assessment was conducted, the intervention design was poor, the entire study population were open to consuming supplemental vitamin D of 15 \(\mu\)g/d (600 IUD) during the study period, irrespective of treatment allocation, this left further ambiguity in terms of true treatment effects as serum 25(OH)D concentrations were not measured at the end of the study, providing no evidence for optimal serum 25(OH)D levels and cognitive function.

Preliminary work from our group shows no effect on global function and domain-specific tasks of executive function and attention, following 6-month vitamin D\(_3\) intervention of 50 \(\mu\)g/d (2000 IUD) in healthy older adults; further work on domain-specific cognitive outcomes is ongoing\(^{(58)}\). Overall evidence from intervention studies is in its early stages, whilst published studies to data are inconclusive. This may be attributable to study design; nevertheless, these shortcomings have helped inform well-designed interventions\(^{(72)}\), findings of which are likely to be available in the near future.

**Vitamin D and Alzheimer’s disease**

Other interventions have been conducted in participants with mild–moderate AD and institutionalised older adults; however both showed no effect, were of short duration and add little in terms of preventable, risk factors for AD. One reported an improvement in attention and reaction times in 139 ambulatory subjects who were sup-

Vitamin D metabolism and the central nervous system

The discovery of 1α-hydroxylase and metabolic pathways for vitamin D in the human brain\(^{(87)}\) and cerebrospinal fluid support a localised catabolic pathway for vitamin D in the central nervous system. The three enzymes necessary for complete synthesis and catabolism of active vitamin D has also been expressed\(^{(88,89)}\). Serum 25(OH)D has also been evidenced to cross the blood–brain barrier a characteristic shared by other neurosteroids\(^{(90)}\).

**Vitamin D receptor and the central nervous system**

The nuclear functions of 1,25-dihydroxyvitamin D\(_3\) are mediated through the VDR, a member of the nuclear receptor family identified in over 2700 genomic sites\(^{(82,91)}\). Experimental scientists have demonstrated the extensive mapping of the VDR in the rat brain\(^{(92–95)}\), showing a similar distribution in human brain tissues\(^{(87)}\), with the earliest evidence in post-mortem brains of AD and Huntington’s disease patients\(^{(87,96)}\). The identification of its distribution in neuronal and glial cells in the human brain followed thereafter, supporting a functional role in light of local production of active vitamin D in the human brain\(^{(87)}\). Areas identified in both animal and human brain tissue show similar patterns\(^{(94)}\), in peripheral neurons,\(^{(97)}\) and in several cell types of the central nervous system\(^{(93,95,98)}\). The action of 1,25-dihydroxyvitamin D\(_3\) upon binding to the VDR has been linked with a diverse range of biological systems such as immune modulation, cell growth and cell differentiation all of which impact brain function via interaction with target genes\(^{(99,100)}\).

**Vitamin D and neuroprotection**

Animal and cell culture evidence suggest that vitamin D may protect the structure and integrity of neurons through detoxification pathways and neurotrophin synthesis\(^{(102)}\). Vitamin D is known to affect the expression of three of the four neurotrophins; nerve growth factor, glial-derived nerve factor and neurotrophin 3\(^{(102)}\). Treatment of vitamin D in adult rats resulted in increased glial-derived nerve factor expression and immunoreactivity after dopamine toxicity damage\(^{(103)}\). Furthermore, vitamin D\(_3\) may attenuate neurotoxicity; administration of calcitriol has been shown to increase levels of antioxidants, such as glutathione in the rat brain which protects oligodendrocytes and the integrity of nerve conduction pathways critical to mental processing\(^{(104)}\). The in vitro analysis shows vitamin D treatment inhibits production TNF-α and IL 6, suggesting an anti-inflammatory role\(^{(105)}\).
**Vitamin D and regulation of intraneuronal calcium**

Elevated levels of calcium in the brain leads to neurotoxicity. Three calcium-binding proteins have been shown to be modulated by vitamin D in brain tissues, calbindin, parvalbumin and calretinin\(^{(106)}\). All three are widely and uniquely distributed in the adult brain and are believed to serve a neuroprotective role as calcium buffers\(^{(107)}\) as well as being involved in critical brain functions. In vitamin D-deficient mice, certain calcium channels are shown to be unregulated leading to an increase in Ca\(^{2+}\)\(^{(108)}\) and in vitro evidence has shown that vitamin D can down-regulate calcium channels\(^{(109)}\).

**Vitamin D and secondary vascular protection**

Vascular dementia is the second most commonly occurring type of dementia after AD, though markedly different can also co-exist as ‘mixed dementia’. Vascular dementia is characterised by cognitive dysfunction secondary to ischemic or haemorrhagic brain lesions due to cerebrovascular disease or CVD. This type of brain damage may result from an influx of excitatory amino acids, inflammatory responses and changes in cell function, which result in excessive calcium entry\(^{(110)}\). With these changes presents an increase in intracellular nitric oxide production and increased oxidative stress.

Vitamin D may help improve vascular-related brain disease by mediating harmful effects of inflammation, calcium dysregulation and increased oxidative stress. During transient ischemic events, transforming growth factor and glial-derived nerve factor are upregulated in hippocampal cells to promote survival\(^{(111)}\). As described earlier, vitamin D enhances innate antioxidative defences by increasing glutathione and glial-derived nerve factor concentrations\(^{(111-113)}\). These particular changes were shown to attenuate ischemic brain disease in rodents\(^{(101)}\).

Furthermore, 1,25 dihydroxyvitamin D inhibits inducible nitric oxide synthetase\(^{(114)}\), an enzyme that is up-regulated during ischaemic events and in patients with AD\(^{(115)}\). It is responsible for generating nitric oxide, which is known to cause damage to neurons and oligodendrocytes at high concentrations\(^{(116)}\).

It is plausible that vitamin D may influence vascular-related dementia via indirect mechanisms. Therapeutic intervention with vitamin D regulates blood pressure\(^{(117,118)}\), cardiac hypertrophy\(^{(119)}\) and plasma rennin activity\(^{(120,121)}\). There is an inverse relationship between vitamin D levels and congestive heart failure\(^{(122)}\) and vitamin D insufficiency is associated with incident CVD\(^{(109)}\).

**Future directions**

All being considered, a functional role for vitamin D in the central nervous system is still not clear but the potential for neuronal and glial cell-specific actions, e.g. proliferation, differentiation and immune modulation are well evidenced in animal models. Research into vitamin D and cognition is likely to benefit from strong collaborations between scientists trained in both disciplines.

Whilst much effort is being made to standardise reporting of vitamin D status, similar standardisation of cognitive outcomes in vitamin D studies would progress our understanding. Current guidelines show that daily supplementation of 50 µg/d (2000 IU/d) is acceptable in community-dwelling adults without medical supervision\(^{(123)}\). In countries where mandatory food fortification is in place, fortification levels remain low and therefore contribute no risk for intoxication, even when supplemental D is adhered to. It is warranted to counsel vitamin D supplementation in this population.

**Conclusion**

Dementia risk is a prominent concern for all individuals, governments and health professionals worldwide. Identification of modifiable risk factors is at the forefront of the ageing research agenda. There is plausible biological evidence for a role of vitamin D status in brain health from animal models. Epidemiological evidence supports this relationship but few randomised controlled trials have been conducted and show inconsistent findings. It is of great importance as vitamin D deficiency is a worldwide pandemic and is seen most commonly in older adults, residing in northerly latitudes and those of non-white ethnicity, particularly during the winter months. We are unable to indicate an optimal 25(OH)D level that may support cognitive function in healthy older adults, it seems at a minimum we should first aim to prevent deficiency through vitamin D public health strategies. There are many unanswered questions regarding a role for vitamin D and cognitive ageing: (1) What, if any, is the optimal level required to support neuroprotection? (2) At what life stage is intervention most likely to optimise brain health? (3) Is the link mediated by other lifestyle factors such as physical function? Well-designed randomised controlled trials using valid comprehensive cognitive assessments are required to determine if raising 25(OH)D concentrations through supplemental vitamin D improves cognitive health and contributes a viable component of lifestyle approaches to maintain brain health.

**Financial support**

N. A. is supported by a scholarship from the Irish Research Council.

**Conflict of interest**

None.

**Authorship**

N. A., B. L. and M. O’S. wrote the manuscript and approved the final draft of the submitted manuscript.
References


40. Brouwer-Brolsma EM, Feskens EJ, Steegenga WT et al. (2013) Associations of 25-hydroxyvitamin D with fasting glucose, fasting insulin, dementia and depression in...


Vitamin D, ageing and cognitive function


78. Eyles DW, Burne THJ & McGrath JJ (2013) Vitamin D effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 34, 47–64.


